Sirtuin Histone deacetylase inhibitor

Phase 2Small molecule

FFederal University of São Paulo

Sirtuin Histone deacetylase inhibitor is one of 32 small molecule programs targeting HIV. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIVRecruiting

HIV-1Completed

HIVPhase 2

Recruiting

HIV-1Preclinical

Completed

Competition

Competitive Landscape

44 competitors in HIV

#DrugCompanyPhaseTrials

Tivicay

GSK

Approved

5 2

Cabenuva

GSK

Approved

2 3

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

6 4

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—5

Epivir

GGlaxo Dba Glaxosmithkline

Phase 3

10 6

INCMGA00012

Incyte

Phase 3

1 7

Fostemsavir

GSK

Phase 3

1 8

Selzentry

GSK

Phase 2

4 9

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 2

2 10

Fosamax

OOrganon and Co

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

HIV

NCT06805656

Clinical

Trials by Indication[1]

HIV-11 trial

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Completed·FFederal University of São Paulo·N/A·NCT02961829·30 enrolled

HIV1 trial

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Use of Antiretrovirals

Recruiting·FFederal University of São Paulo·Phase 2·NCT06805656·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sirtuin Histone deacetylase inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sirtuin Histone deacetylase inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sirtuin Histone deacetylase inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal University of São Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFederal University of São Paulo

Sirtuin Histone deacetylase inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

HIV-11 trial

HIV1 trial

References

Drug Info

Quick Facts

Related News